Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Author:

Schmid Peter1,Cortes Javier1ORCID,Dent Rebecca1,Pusztai Lajos1,McArthur Heather1,Kümmel Sherko1,Bergh Jonas1,Denkert Carsten1,Park Yeon Hee1ORCID,Hui Rina1,Harbeck Nadia1,Takahashi Masato1ORCID,Untch Michael1,Fasching Peter A.1,Cardoso Fatima1,Andersen Jay1,Patt Debra1,Danso Michael1,Ferreira Marta1,Mouret-Reynier Marie-Ange1,Im Seock-Ah1,Ahn Jin-Hee1,Gion Maria1,Baron-Hay Sally1,Boileau Jean-François1,Ding Yu1,Tryfonidis Konstantinos1,Aktan Gursel1,Karantza Vassiliki1,O’Shaughnessy Joyce1

Affiliation:

1. From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer Center, Quironsalud Group, and Vall d’Hebron Institute of Oncology, Barcelona (J.C.), and the Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid (J.C.), and Ramon y Cajal University Hospital (M.G.), Madrid; the National Cancer Center Singapore, Duke–National University of Singapore Medical School, Singapore (R.D.); Yale School of Medicine, Yale Cancer...

Funder

Merck & Co., Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Cited by 612 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3